Investors should understand in detail a company's operating structures and how those structures can affect there P&L. Abbott is a highly diversified company with manufacturing, R&D and SG&A operations located in areas of point of sale. With geographical operation costs lined with geographical revenue there is a lot less impact due to currency fluctuation on the bottom line (EPS) along with good currency hedge programs.
Your are right. The low information investors do not know the science behind Pharmacyclics and ABT199 and other drug combos. Nor do they understand the market entry strategy for these products. That is what happens when you are a short term thinker.